GlassScriptPhysician profile
Paul J Sietmann
NPI 1558356162
$6,880.07
in general payments reported to CMS, 2019-2025
26 companies · $1,361 in 2025
The $1,361 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,600 · 2020: $92.82 · 2021: $214 · 2022: $977 · 2023: $1,085 · 2024: $550 · 2025: $1,361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,970 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,970.41 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $1,431.42 | 2019-2025 | Lipiflow System Activator (Disposable) |
| Alcon Vision LLC | $1,358.88 | 2019-2025 | Rocklatan, Clareon, Rhopressa |
| Sun Pharmaceutical Industries INC. | $799.71 | 2019-2025 | Cequa |
| Abbvie INC. | $782.35 | 2023-2025 | Vuity, Xen Glaucoma Treatment System, Durysta |
| Novartis Pharmaceuticals Corporation | $331.00 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $317.66 | 2023-2025 | Envista Envy Iol, Xiidra, Vyzulta |
| Rxsight INC | $286.81 | 2021-2025 | Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Aerie Pharmaceuticals, INC. | $217.82 | 2019-2020 | |
| Oyster Point Pharma, INC. | $186.69 | 2022-2023 | Tyrvaya |
| Lumenis Be INC | $168.50 | 2023 | Optilight |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $125.08 | 2019-2021 | |
| Dompe US, INC. | $123.77 | 2025 | Oxervate |
| Genzyme Corporation | $121.35 | 2019 | |
| Coopervision INC. | $118.67 | 2019 | |
| Biotissue Holdings INC. | $94.89 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lkc Technologies, INC. | $88.85 | 2023 | |
| Astellas Pharma US INC | $67.93 | 2023-2025 | Izervay |
| Amgen INC. | $57.65 | 2025 | Tepezza |
| Allergan, INC. | $37.81 | 2019-2021 | |
| Thea Pharma INC. | $37.14 | 2024-2025 | Iyuzeh |
| Eyevance Pharmaceuticals LLC | $24.19 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $23.12 | 2025 | Syfovre |
| Glaukos Corporation | $22.91 | 2025 | Idosetr |
| Sight Sciences, INC. | $19.77 | 2025 | Omni Surgical System |
| Harrow Eye, LLC | $18.98 | 2025 | Vevye |
| Tarsus Pharmaceuticals, INC. | $17.12 | 2025 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Sietmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.